Jazz Pharmaceuticals (JAZZ) Stock Analysis & AI Equity Report
Jazz Pharmaceuticals (JAZZ) overview
Jazz Pharmaceuticals (JAZZ) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4,268m and operating profit of USD -430m; the year-end share price was 170.00 USD and market capitalisation was USD 10,444m. Jazz Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Jazz Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for rare diseases and patients with limited treatment options. Its portfolio includes therapies for epilepsies, cancers and sleep disorders, including Xywav, Epidiolex, Ziihera, Modeyso, Zepzelca and Rylaze. The company develops therapies through research and development programs and markets approved medicines to patients and healthcare providers in multiple countries.
Generate the Jazz Pharmaceuticals report
Jazz Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Jazz Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Jazz Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.